|
|
 |
|
|
 |
 |
|
 |
| BioAnalab has a staff of qualified scientists with many years of experience in analytical development, contract research services, academic research, development of biopharmaceuticals and clinical diagnostics.
A dedicated team including the project manager and senior laboratory scientist is allocated to each project. They are supported by an experienced postdoctoral scientist who acts as scientific reviewer in addition to an independent QA reviewer. We also have an expert panel of scientific, regulatory and clinical advisors to provide specialist input when required.
BioAnaLab is a rapidly growing company and is always seeking meticulous and well motivated scientists to join its team. The company welcomes enquiries direct from potential candidates. It does not accept applications through recruitment agencies.
|
|
 |
BioAnalab has modern air-conditioned laboratories in Florey House at the heart of the Oxford Science Park. There are excellent staff amenities with ample parking, catering and child-care facilities on site. We offer a competitive basic salary, with a pension scheme, bonus scheme and share option scheme.
We welcome enquiries from science graduates who are meticulous
and prepared to work hard to meet customer deadlines. Each of our client projects is unique and there are opportunities to
develop and use new technologies. We provide a comprehensive training package and a variety of career routes within the company.
If you are interested to find out more, send your CV with a covering letter directly to Human Resources, BioAnaLab Limited, Florey House,
3 Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GP, UK, or by email to human.resources
@bioanalab.com
Please note that we never consider any applications submitted by recruitment agencies. |
|
 |
|
 |
 |
Geoff Hale,
Chief Executive Officer |
Geoff is Visiting Professor of Therapeutic Immunology at the Sir William Dunn School of Pathology, University of Oxford. He has worked for over 25 years with Professor Hermann Waldmann to develop a range of therapeutic monoclonal antibodies, notably Campath®.
Geoff obtained his PhD in Biochemistry at Cambridge in 1977 and trained as a protein chemist, before joining the Pathology Department at Cambridge. In 1980 he discovered the CD52 antigen and characterised its structure and the biological activity of Campath antibodies.
In 1990 he established the Therapeutic Antibody Centre, which moved to Oxford in 1995, and became the leading academic GMP facility for manufacture of monoclonal antibodies. He coordinated a world-wide group of clinicians who used these antibodies for clinical trials in more than 5,000 patients. This work made an important contribution to the current strong position of antibodies as drug candidates and led to the licensing of seven monoclonal antibodies to the pharmaceutical industry.
Geoff is one of the scientific founders of TolerRx Inc, a US biopharmaceutical company which is developing new therapies for induction of tolerance.
In 2002 he founded BioAnaLab to provide analytical services to the pharmaceutical industry and in 2004 became its Chief Executive Officer.
|
|
Chris Cox,
Director of Clinical Services |
Chris was awarded a PhD in 1993 for studies on cellular mechanisms involved in multiple drug resistance. At the University of York he did 4 years post-doctoral research investigating the role of intracellular signal transduction in pre-implantation embryo development.
In 1996 he moved to the Biotechnology section of Covance in Harrogate. Here his interests ranged from protein analysis to bioanalytical immunoassays. Before he joined BioAnaLab his main focus was on the development, validation and use of biological potency assays. He was involved in a great number of studies and developed an expert knowledge in the validation of analytical methods, equipment qualification and software validation.
At BioAnaLab, Chris has overall responsibility for running the service laboratory, for liaising with clients and in the development of the expanding range of specialised assays for biopharmaceuticals. |
 |
Patrick Harrison,
Quality Assurance Manager |
Patrick's experience of quality systems and regulatory affairs includes biologics manufacturing, medical devices, veterinary products and analytical services. Originally trained in the Blood Transfusion Laboratory and the Department of Surgery (under Prof Sir Roy Calne) at Cambridge University, Patrick was instrumental in establishing the quality system of the Therapeutic Antibody Centre, which eventually led to its successful licensing as one of the first academic GMP facilities for production of investigational biologic drugs. He subsequently worked at Abbott MediSense where he was responsible for product registration, internal auditing and site-wide Quality System training. After a period as Quality Assurance Manager at Intervet UK, he joined BioAnaLab in 2005.
Among his current responsibilities, Patrick oversees the Quality System, staff training and validation of equipment and software.
|
 |
 |
David Oxlade,
Chairman |
David Oxlade is an experienced health care business executive; until recently a Director and Chief Executive of Xenova Group plc. David is also a Non-Executive Director of Cobra Biomanufacturing plc.
During his career, David has been involved in the development of a number of public and private innovative healthcare businesses in Europe, North America and Asia. Prior to joining the Xenova Group, David held managerial and Board level positions with several international and global companies, including that of President of Syva Company, the California based subsidiary of Hoechst AG, ICI Diagnostics, Boehringer Mannheim GmbH (now part of Roche) and Glaxo Research. |
Geoff Hale, Founder and CEO
(biography)
Chris Cox, Director of Clinical Services
(biography) |
 |
Matthew Frohn,
Non-Executive Director representing Oxford Technology 3 Venture Capital Trust |
| Matthew is a Director of Seed Capital Ltd, the fund adviser to the Oxford Technology Venture Capital Trusts and an investor in BioAnaLab. In 1999, he completed his doctorate in developmental genetics at the University of Oxford before crossing the floor into venture capital where he specialises in early stage investments in the life science industry. Through the four Oxford Technology VCTs, he is involved with a variety of healthcare companies, including ventures in vaccines, cancer therapeutics, drug delivery, resorbable implants and, of course, this biopharmaceuticals CRO. |
 |
Flic Gabbay,
Non-Executive Director representing Oxford University |
Flic has more than 25 years’ experience as a pharmaceutical physician, working as CEO, Director or Vice President in large pharma, biotech and contract research. Flic now mainly works as a consultant in clinical and regulatory affairs, specialising in anti-infective development. She is also Director of Education at the Drug Safety Research Unit in Southampton, an Honorary Senior Lecturer at the University of Portsmouth and Non Executive Chair of Phico Therapeutics.
She has worked on a wide range of drug development programmes both with NCEs and biotech, including recombinant proteins, monoclonal anditodiess and transgenic proteins. She worked for Warner Lambert Parke Davis for nine years, latterly as Regional Clinical Research Director responsible for N.Europe, Australia and S. Africa and spent a spell in the US as Worldwide Head of Anti Infective Drug Development. Flic holds degrees in Pharmacology, Medicine and Surgery and is a Fellow of the Royal College of Physicians. She was involved in the founding of the Society of Pharmaceutical Medicine and the Faculty of Pharmaceutical Medicine. She has sat on a number of expert academic, public and regulatory advisory boards relating to drug development. |
 |
|
Through a network of clinical and scientific advisors, BioAnalab has access to a wide range of medical expertise including immunology, haematology, transplant surgery, neurology, rheumatology and infectious diseases. These individuals all have many years experience with the clinical development of biopharmaceuticals and are well positioned to support the company in its mission to provide a service with a very real depth of understanding.
|
 |
|
|
 |
 |
|
